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Glucocorticoid-Remediable Aldosteronism: An Uncommon and Often Overlooked 
Cause of Adrenal Hypertension  
Sindhu Bhat, MD; Larry N. Merkle, MD
Introduction:
Case Presentation:
Figure: CT of Abdomen with contrast 
showing right adrenal nodular lesion and 
left adrenal limb thickening representing 
hyperplasia.
Glucocorticoid-Remediable	Aldosteronism	(GRA)	is	a	rare	form	of	
hyperaldosteronism.	Early	recognition	of	this	problem	in	a	hypertensive	
patient	not	responding	to	the	usual	hypertensive	medications	can	help	
prevent	serious	complications	of	hypertension.		
•		A	66	year	old	male	with	a	long	standing	history	of	hypertension	which	was	
apparently	well	controlled	initially,	recently	had	accelerated	hypertension	
not	responding	to	multiple	medications	which	included	Bystolic,	
Amlodipine,	Diovan	and	Minoxidil.
•		His	BP	was	over	180s/100s	and	at	times	was	in	the	200s/100s.
•		His	past	medical	history	included	Hypercholesterolemia,	Diabetes	and	
Hypertension.		
•		His	father	had	Hypertension	and	had	died	
of	a	stroke	in	his	early	60s	and	his	son	has	
Hypertension.
•		Labs:	Metanephrines	and	Normetanephrines	
which	were	high.	{Metanephrine-318mcg/
24h	(Normal	90-315),	Normetanephrine-
1080mcg/24h	(Normal	122-676)	and	Total	
Metanephrines-1398mcg/24h	(Normal	224-
832)}.	He	also	had	hypokalemia	and	was	on	
potassium	replacement	at	home.	Plasma	
Aldosterone	level	was	17ng/dl	which	is	in	the	
high	normal	range,	renin	was	<	0.5ng/ml/hr	
which	is	low	and	ACTH		was	11pg/ml	which	
was	normal.	His	urine	free	cortisol	was	17	
mcg/h	which	was	normal.	
•		CT	scan	of	abdomen	showed	a	right	adrenal	
nodular	mass	and	left	adrenal	hyperplasia.	
Intervention and Treatment:
•		Right	adrenalectomy	was	done	for	a	possible	Pheochromocytoma	vs	
Primary	Hyperaldosteronism.
•		Histopathology	showed	diffuse	micronodular	and	macronodular	adrenal	
hyperplasia	and	the	adrenal	medulla	was	normal.	
•		There	was	little	improvement	in	blood	pressure	post-op	and	the	
hypokalemia	persisted.	
•		Post-op	Aldosterone	level	was	39ng/dl	and	27ng/dl	on	2	separate	
readings	2	months	after	surgery.	
•		After	reviewing	the	literature	it	was	suspected	that	the	patient	had	
underlying	Glucocorticoid-Remediable	Aldosteronism.	He	was	then	
started	on	Dexamethasone	2mg	which	promptly	improved	his	BP	and	
resolved	his	Hypokalemia	and	Aldosterone	level	was	11ng/dl	1	month	
after	starting	Dexamethasone.	
•		Patient’s	BP	is	currently	130s/70s	and	his	medications	include	
Dexamethasone	1mg,	Aspirin,	Simvastatin	,	Bystolic	10mg	every	other	
day	and	Aldactone	100mg	daily.
•		Patient	is	currently	awaiting	genetic	testing	and	subsequently	an	MRA	
for	screening	of	intracranial	aneurysms.	
Conclusion:
Glucocorticoid-Remediable	Aldosteronism	is	a	fairly	rare	cause	of	
Hyperaldosteronism	which	should	be	considered	in	the	differential	
diagnosis	of	secondary	causes	of	hypertension	especially	when	there	is	a	
strong	family	history	of	severe	refractory	hypertension.	
Discussion:
•		There	are	few	published	case	reports	of	patients	with	GRA.
•		It	is	an	autosomal	dominant	form	of	aldosteronism	which	results	from	a	
chimeric	gene	for	the	enzyme	aldosterone	synthase.
•		It	has	been	shown	to	be	caused	by	a	hybrid	gene	mutation	formed	by	a	
cross-over	of	genetic	material	between	the	ACTH-responsive	regulatory	
portion	of	the	11b-hydroxylase	(CYP11B1)	gene	and	the	coding	region	of	
the	aldosterone	synthase	(CYP11B2)	gene.	
•		ACTH	stimulates	the	expression	and	secretion	of	aldosterone	in	the	
Zona	Fasciculata,	which	is	normally	controlled	by	the	renin	axis.	
•		Plasma	aldosterone	is	elevated	and	plasma	renin	activity	is	suppressed,	
but	the	aldosterone-renin	ratio	is	typically	not	as	high	as	with	primary	
hyperaldosteronism	caused	by	an	aldosterone-producing	adenoma.
Regulation	of	Aldosterone	synthesis	in	GRA
Chimeric	gene	duplication	in	glucorticoid-remediable	
aldosteronism.	P=	promoter	sequence.	C=	coding	sequence.
•		It	is	also	characterised	by	the	production	of	two	rare	steroids,	
18hydroxycortisol	and	18oxocortisol.	
•		Aldosterone	suppression	by	dexamethasone,	
and	high	18-hydroxycortisol	and	18-
oxocortisol	levels	are	used	to	differentiate	
glucocorticoid-remediable	aldosteronism	
(GRA)	from	other	forms	of	primary	
aldosteronism.	Diagnosis	is	confirmed	by	
genetic	testing.	
•		Treatment	with	physiological	doses	of	
glucocorticoid	will	correct	the	oversecretion	
of	aldosterone	by	suppressing	ACTH	
and	will	lower	the	blood	pressure	and	
correct	the	hypokalemia.	Treatment	with	
mineralocorticoid	receptor	antagonist	in	these	
patients	may	be	just	as	effective.	
•		Analysis	of	affected	patients	has	
demonstrated	a	high	prevalence	of	early	
cerebral	hemorrhage,	largely	as	a	result	of	
aneurysms.	
